I TUOI DATI
I TUOI ORDINI
N. prodotti: 0
Totale ordine: € 0,00
I TUOI ABBONAMENTI
I TUOI ARTICOLI
Rivista sulle Malattie del Sistema Endocrino
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,118
Minerva Endocrinologica 2016 Nov 03
Novel acquisitions in the diagnosis of medullary thyroid carcinoma
Pierpaolo TRIMBOLI 1, Anna CRESCENZI 2, Enrico SAGGIORATO 3, Giorgio TREGLIA 1, Luca GIOVANELLA 1 ✉
1 Department of Nuclear Medicine and Thyroid Centre, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; 2 Section of Pathology, University Hospital Campus Bio Medico, Rome, Italy; 3 Service d’Endocrinologie, Pôle de Médecine, Centre Hospitalier des Escartons, Briançon, France
BACKGROUND: The correct identification of medullary thyroid carcinoma (MTC) has been a challenge since its first description. In the last years some advances in this context have been achieved. Here we aimed to review and discuss published data on the more recent acquisition in the diagnosis of MTC.
METHODS: A literature search of the medical databases was conducted by searching papers reporting tool for diagnosis of MTC published in the last years. The search was updated until July 2016.
RESULTS: The literature search revealed several relevant articles which focused on different topics of the diagnosis of MTC. The results are reported by four paragraphs, such as 1. Fine-needle aspiration; 2. Molecular analysis; 3. Serum markers; 4. Imaging.
CONCLUSIONS: The measurement of calcitonin in FNA washout fluids is essential due to poor accuracy of conventional cytology to detect MTC. Genetic analysis can help to identify those advanced MTC with poorer prognosis who do not respond to chemotherapy. Procalcitonin may in the next future replace calcitonin as serum diagnostic marker of MTC. Recent evidence based data seem to suggest the emerging role of functional imaging in recurrent MTC in patients with calcitonin serum levels > 150 pg/ml.